Publications by authors named "J Ingwersen"

Background: This preliminary retrospective cohort study investigates the potential additive prophylactic effect of erenumab, a fully human monoclonal antibody that blocks the calcitonin gene-related peptide receptor, in combination with ongoing onabotulinumtoxin A (onaBoNT-A) treatment in patients suffering from chronic migraine.

Methods: The study included 218 patients and investigated the effects of adding erenumab to the existing treatment regimen. The primary outcome was the MIDAS (Migraine Disability Assessment) score assessed 3 months after the introduction of erenumab.

View Article and Find Full Text PDF
Article Synopsis
  • Retinal optical coherence tomography (OCT) serves as a biomarker for tracking disease progression in relapsing-remitting multiple sclerosis (RRMS), although the changes in retinal layers for progressive MS remain uncertain.
  • Analyzing data from 195 RRMS, 87 secondary progressive MS (SPMS), 125 primary progressive MS (PPMS), and 98 control patients, researchers found that certain retinal layer thicknesses could predict relapses and MRI activity in various MS types.
  • However, the variability in measuring retinal thickness limits the effectiveness of longitudinal assessments for individual patients.
View Article and Find Full Text PDF

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) of still unclear etiology. In recent years, the search for biomarkers facilitating its diagnosis, prognosis, therapy response, and other parameters has gained increasing attention. In this regard, in a previous meta-analysis comprising 22 studies, we found that MS is associated with higher nitrite/nitrate (NOx) levels in the cerebrospinal fluid (CSF) compared to patients with non-inflammatory other neurological diseases (NIOND).

View Article and Find Full Text PDF
Article Synopsis
  • - The study focused on hospitalized COVID-19 patients with no prior neurological issues to examine the prevalence of neurological problems using objective tests, finding that 66% showed peripheral nerve issues and 33% had central nervous system problems.
  • - It highlighted that 63% of patients assessed for cognitive function demonstrated cognitive impairments, indicating a significant impact on brain health.
  • - Additionally, the research identified specific neurological abnormalities, like issues with somatosensory evoked potentials, as independent risk factors for increased mortality, suggesting that these tests could help predict patient outcomes.
View Article and Find Full Text PDF

Ocrelizumab is a B cell-depleting drug widely used in relapsing-remitting multiple sclerosis (RRMS) and primary-progressive MS. In RRMS, it is becoming increasingly apparent that accumulation of disability not only manifests as relapse-associated worsening (RAW) but also as progression independent of relapse activity (PIRA) throughout the disease course. This study's objective was to investigate the role of PIRA in RRMS patients treated with ocrelizumab.

View Article and Find Full Text PDF